title: Langerhans cells in benign, premalignant and malignant skin lesions of renal transplant recipients and the effect of retinoid therapy.
abstract: METHODS
  Langerhans cells (LC) are a unique population of antigen-presenting cells in the epidermis which may play a role in the defense mechanisms against skin tumors. Renal transplant recipients (RTRs) have a significantly increased incidence of premalignant and malignant skin lesions. Langerhans cells, which are important for local immune surveillance, may be depleted or downregulated in skin neoplasms of RTRs, facilitating their growth. We investigated the Langerhans cell densities in 29 squamous cell carcinomas (SCCs), five basal cell carcinomas (BCCs), four Bowen's disease, eight dysplastic lesions (actinic keratoses), and three viral warts from 15 RTRs and compared these to the Langerhans cell densities in normal control skin. Eleven RTRs were receiving low-dose etretinate as chemoprophylaxis for recurrent skin cancer and the effect of low-dose retinoid therapy on Langerhans cell densities in SCCs from these patients was also assessed. Langerhans cells in frozen tissue sections were stained with the anti-human Leu-6 monoclonal antibody.
  
  
  RESULTS
  There was no significant difference in LC numbers between normal skin from RTRs and normal skin from non-immunosuppressed individuals. There was a statistically significant reduction in LC/mm2 and LC/1000 K (keratinocytes) for SCC, BCC, dysplastic lesions and viral warts compared with normal skin (P < 0.001, P < 0.01, P < 0.001, P < 0.05, respectively). There was a trend for an increase in Langerhans cell density in SCCs which developed during etretinate therapy compared with pre-etretinate but the difference was not statistically significant.
  
  
  CONCLUSIONS
  In this study of RTRs, a significant reduction in Langerhans cell densities was observed in SCCs, BCCs and dysplastic lesions compared with normal skin. A reduction in Langerhans cell density in viral warts from RTRs was also observed. A working hypothesis may include a multifactorial etiology for this reduction in Langerhans cell densities. It is possible that human papilloma virus (HPV) infection, by reducing intraepidermal Langerhans cell density, may decrease local immune surveillance and facilitate the development of skin cancers. Ultraviolet radiation and immune suppression may also play a role. The marked depletion of Langerhans cells in skin cancers, precursor lesions and viral warts suggests a central role for Langerhans cells in skin cancer promotion in RTRs.
authors.affiliation: Department of Dermatology, Beaumont Hospital, Dublin, Ireland. gibson.gillian@mayo.edu
authors.forename: G E
authors.initials: GE
authors.lastname: Gibson
authors.forename: A
authors.initials: A
authors.lastname: O'Grady
authors.forename: E W
authors.initials: EW
authors.lastname: Kay
authors.forename: M
authors.initials: M
authors.lastname: Leader
authors.forename: G M
authors.initials: GM
authors.lastname: Murphy
mesh_terms: D002280:Basal Cell Carcinoma / Q000188:drug therapy / Q000473:pathology; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000473:pathology; D002452:Cell Count / Q000187:drug effects; D005050:Etretinate / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007641:Keratolytic Agents / Q000008:administration & dosage*; D016030:Kidney Transplantation / Q000473:pathology*; D007801:Langerhans Cells / Q000187:drug effects* / Q000473:pathology*; D008297:Male; D011230:Precancerous Conditions / Q000188:drug therapy / Q000473:pathology; D012680:Sensitivity and Specificity; D012871:Skin Diseases / Q000188:drug therapy* / Q000473:pathology*; D012878:Skin Neoplasms / Q000188:drug therapy / Q000473:pathology; D018709:Statistics, Nonparametric
chemical_list: D007641:Keratolytic Agents; D005050:Etretinate